Navigation Links
Jonesing for java: Could caffeine use predict risk for cocaine abuse?

Parents of young caffeine consumers take heed: that high-calorie energy drink or soda might present more than just obesity risk. In fact, according to a double-blind, placebo-controlled study that examined responses to stimulants, an individual's subjective response to caffeine may predict how he or she will respond to other stimulant drugs, possibly reflecting differences in risk for abuse of other more serious drugs of abuse, such as amphetamine and cocaine.

The new findings are reported in the November issue of the journal Drug and Alcohol Dependence by Stacey Sigmon, Ph.D., associate professor of psychiatry at the University of Vermont College of Medicine, a drug abuse researcher whose previous studies have looked at caffeine withdrawal and interactions between psychomotor stimulants and cigarette smoking.

"People differ dramatically in how they respond to drugs," says Sigmon. "For example, a single dose of a drug can produce completely opposite effects in two people, with one absolutely loving and the other hating the drug's effects. It is important to improve our understanding of these differences, as they may reflect key individual differences in vulnerability or resilience for drug abuse," adds Sigmon, who, with colleagues from Johns Hopkins University, examined how individual differences in response to caffeine might predict a person's subsequent response to d-amphetamine, a classic psychomotor stimulant with similar effects to other commonly-abused stimulants like cocaine.

Sigmon and coauthor Roland Griffiths, Ph.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, first employed a choice procedure (Phase 1) to identify participants as caffeine "Choosers" and "Nonchoosers" for the study. Choosers were those who chose caffeine over placebo in the majority (>/= 7) of 10 choice session and Nonchoosers chose placebo over caffeine in the majority of choice sessions. There were no significant differences regarding pre-study caffeine intake or other characteristics between the two groups. During the second phase of the study, all participants received various doses of d-amphetamine and rated how much they liked or disliked each dose. The researchers found that caffeine Choosers reported significantly more positive subjective effects and fewer negative/unpleasant effects of d-amphetamine compared to Nonchoosers, particularly at the highest doses. On the other hand, caffeine Nonchoosers reporter fewer positive effects and more unpleasant effects of d-amphetamine compared to Choosers.

According to Sigmon and Griffiths, the study is the first to demonstrate that caffeine reinforcement prospectively predicts the positive subjective effects of another drug.

"While these data do not mean that every coffee lover is at risk for proceeding to cocaine abuse," says Sigmon, "this study does show that individuals vary markedly in their subjective and behavioral response to psychomotor stimulants, and those for whom a modest caffeine dose serves as a reinforcer are the same folks who subsequently report more positive subjective effects of d-amphetamine. Future research will be important to examine whether caffeine reinforcement predicts vulnerability to reinforcement and abuse of classic psychomotor stimulants such as amphetamine and cocaine."

A total of 22 participants completed the study, which took place over a 10- to 14-week timeframe and was supported by funding from the National Institute on Drug Abuse.


Contact: Jennifer Nachbur
University of Vermont

Related medicine news :

1. Brewing up a gentler java: Dark-roasted coffee contains stomach-friendly ingredient
2. New method to diagnose sinusitis could reduce use of antibiotics
3. Marijuana component could ease pain from chemotherapy drugs
4. Anemia Could Add to Surgical Risks
5. Could Surgery, Anesthesia While Very Young Hamper Kids Development?
6. Penn-developed online informed consent tool could boost number of patients in cancer clinical trials
7. City College of New York-led research could lead to wearable sensors for the blind
8. University of Missouri study finds risk factors for cat cancer, could have human implications
9. How global warming could cause animals to shrink
10. Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns
11. Could Too Little Vitamin B-12 Shrink the Aging Brain?
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... Vegas, NV (PRWEB) , ... November 25, 2015 , ... ... invites patients to learn more about hair loss treatment with the Capillus272™ Pro laser ... an effective solution for thicker and fuller hair, without the need for surgery, prescription ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: